基于模型的指导格卡瑞韦哌仑他韦治疗慢性丙型肝炎，以确定超短疗程患者。
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.
机构信息
The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois, USA.
Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan.
出版信息
J Infect Dis. 2020 Sep 1;222(7):1165-1169. doi: 10.1093/infdis/jiaa219.
Abstract
We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.
摘要
我们最近在一项概念验证研究中表明，基于实时建模的反应指导治疗可以缩短索磷布韦-维帕他韦、艾尔巴韦-格拉瑞韦和索磷布韦-达拉他韦的丙型肝炎病毒治疗时间，而不影响疗效，这证实了我们对 >200 名患者的回顾性建模报告。然而，尚未对哌仑他韦-格卡瑞韦（P/G）治疗进行回顾性建模。在本研究中，对 44 名肝硬化和非肝硬化患者的丙型肝炎病毒动力学建模预测，P/G 治疗可能分别减少到 16%、34%和 14%的患者的 4、6 和 7 周。这些结果支持进一步评估使用 P/G 的基于建模的反应指导治疗方法。
相似文献
1
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.基于模型的指导格卡瑞韦哌仑他韦治疗慢性丙型肝炎，以确定超短疗程患者。
J Infect Dis. 2020 Sep 1;222(7):1165-1169. doi: 10.1093/infdis/jiaa219.
2
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.格卡瑞韦哌仑他韦联合治疗丙型肝炎病毒的简化监测：一项随机非劣效性试验。
J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23.
3
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.格卡瑞韦/哌仑他韦治疗初治慢性 HCV 基因型 1-6 且代偿期肝硬化患者 8 周：EXPEDITION-8 试验。
J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.
4
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.格卡瑞韦和哌仑他韦在无肝硬化的 HCV 基因 1-6 型患者中产生高应答率。
J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13.
5
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.索磷布韦、格卡瑞韦、哌仑他韦和利巴韦林作为难治性丙型肝炎患者的挽救疗法
Hepatology. 2021 Oct;74(4):2304-2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16.
6
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.慢性丙型肝炎病毒患者对当前代直接作用抗病毒药物治疗失败的病毒学模式。
Int J Antimicrob Agents. 2020 Sep;56(3):106067. doi: 10.1016/j.ijantimicag.2020.106067. Epub 2020 Jun 26.
7
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.索磷布韦/维帕他韦±利巴韦林与格卡瑞韦/哌仑他韦治疗基因 3 型丙型肝炎病毒感染患者的疗效和安全性。
Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7.
8
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).格拉瑞韦/艾尔巴韦和格卡瑞韦/哌仑他韦治疗晚期慢性肾脏病患者的丙型肝炎：来自德国丙型肝炎注册研究（DHC-R）的数据。
Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):76-83. doi: 10.1097/MEG.0000000000001923.
9
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.3 周反应指导的三联直接作用抗病毒治疗慢性丙型肝炎感染的疗效和安全性：一项 2 期、开放标签、概念验证研究。
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. doi: 10.1016/S2468-1253(16)30015-2. Epub 2016 Jul 25.
10
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.真实世界中 glecaprevir/pibrentasvir 治疗慢性丙型肝炎感染的疗效和安全性：来自德国丙型肝炎注册研究的数据。
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.
引用本文的文献
1
Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum.基于模型的妊娠和产后丙型肝炎反应导向治疗
Open Forum Infect Dis. 2023 Jan 20;10(2):ofad027. doi: 10.1093/ofid/ofad027. eCollection 2023 Feb.
2
Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.丙型肝炎病毒动力学数学模型的数据参数估计与学习进展。
Mathematics (Basel). 2022 Jun 2;10(12). doi: 10.3390/math10122136. Epub 2022 Jun 19.
3
Utility of On-Treatment Viral Loads During Treatment With Direct-Acting Antivirals in Patients Infected With Chronic Viral Hepatitis C.慢性丙型肝炎病毒感染患者接受直接抗病毒药物治疗期间治疗中病毒载量的效用
J Pharm Technol. 2022 Aug;38(4):213-217. doi: 10.1177/87551225221092598. Epub 2022 Jun 4.
4
Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.基于模型的应答引导直接抗病毒药物疗法治疗慢性丙型肝炎以确定可缩短治疗疗程的个体。
Open Forum Infect Dis. 2022 Mar 22;9(5):ofac157. doi: 10.1093/ofid/ofac157. eCollection 2022 May.
5
Machine learning for mathematical models of HCV kinetics during antiviral therapy.机器学习在抗病毒治疗期间 HCV 动力学数学模型中的应用。
Math Biosci. 2022 Jan;343:108756. doi: 10.1016/j.mbs.2021.108756. Epub 2021 Dec 6.
6
Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C.在使用格卡瑞韦/哌仑他韦治疗丙型肝炎的情况下，急性肾损伤表现为肝肾综合征。
ACG Case Rep J. 2021 May 12;8(5):e00587. doi: 10.14309/crj.0000000000000587. eCollection 2021 May.
7
HCVMultiscaleFit: A Simulator For Parameter Estimation in Multiscale Models Of Hepatitis C Virus Dynamics.HCV多尺度拟合：丙型肝炎病毒动力学多尺度模型中用于参数估计的模拟器
AIP Conf Proc. 2020;2293. doi: 10.1063/5.0026600. Epub 2020 Nov 25.
8
Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics.病毒性肝炎动力学常微分方程模型和偏微分方程模型参数估计的有效方法
Mathematics (Basel). 2020 Sep;8(9). doi: 10.3390/math8091483. Epub 2020 Sep 2.
9
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.针对慢性丙型肝炎感染患者减少直接抗病毒药物疗程的反应引导治疗：一项试点研究。
Sci Rep. 2020 Oct 20;10(1):17820. doi: 10.1038/s41598-020-74568-x.
10
Modeling based response guided therapy in subjects with recent hepatitis C infection.基于模型的反应指导治疗在近期丙型肝炎感染患者中的应用。
Antiviral Res. 2020 Aug;180:104862. doi: 10.1016/j.antiviral.2020.104862. Epub 2020 Jun 25.
本文引用的文献
1
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.格卡瑞韦/哌仑他韦治疗初治慢性 HCV 基因型 1-6 且代偿期肝硬化患者 8 周：EXPEDITION-8 试验。
J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.
2
Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.一名基因型 2aHCV 感染的血液透析患者在 8 周的 glecaprevir 和 pibrentasvir 治疗失败后，接受 12 周的 glecaprevir 和 pibrentasvir 治疗获得成功。
Clin J Gastroenterol. 2020 Apr;13(2):267-270. doi: 10.1007/s12328-019-01039-w. Epub 2019 Aug 28.
3
A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.一种丙型肝炎病毒动力学多尺度模型的参数估计方法。
Bull Math Biol. 2019 Oct;81(10):3675-3721. doi: 10.1007/s11538-019-00644-7. Epub 2019 Jul 23.
4
Utility of viral kinetics in HCV therapy - It is not over until it is over?病毒动力学在丙型肝炎病毒治疗中的作用——未到结束时，焉知已结束？
Liver Int. 2019 May;39(5):815-817. doi: 10.1111/liv.14047.
5
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.在 DAA 作用下的 HCV 早期病毒动力学可能会优化代偿性肝硬化患者的治疗持续时间。
Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.
6
EASL Recommendations on Treatment of Hepatitis C 2018.2018年欧洲肝脏研究学会丙型肝炎治疗推荐意见
J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.
7
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.丙型肝炎病毒（HCV）动力学和模型分析预测，在慢性HCV感染患者中，使用达卡他韦和阿舒瑞韦联合治疗的治愈时间会更短。
PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.
8
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.3 周反应指导的三联直接作用抗病毒治疗慢性丙型肝炎感染的疗效和安全性：一项 2 期、开放标签、概念验证研究。
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104. doi: 10.1016/S2468-1253(16)30015-2. Epub 2016 Jul 25.
9
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.丙型肝炎病毒动力学和模型分析表明，在索非布韦与达卡他韦、西米普韦或来迪帕司韦的联合治疗方案中，达到治愈的时间相似。
J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.
10
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.静脉注射水飞蓟宾实现病毒学持续应答：通过丙型肝炎病毒动力学实时建模进行个体化无干扰素治疗。
Liver Int. 2015 Feb;35(2):289-94. doi: 10.1111/liv.12692. Epub 2014 Oct 10.
Zotero 插件